Venrock eyes 70x return on Lilly-Kelonia deal

Eli Lilly plans to pay $3.25 billion upfront for Kelonia Therapeutics, with the deal potentially reaching $7 billion if milestones are met. Venrock could realize as much as a 70x return from the acquisition, according to partner Bryan Roberts. The transaction underscores continued strong M&A activity in biotech and is a favorable outcome for venture investors.

Analysis

Eli Lilly plans to pay $3.25 billion upfront for Kelonia Therapeutics, with the deal potentially reaching $7 billion if milestones are met. Venrock could realize as much as a 70x return from the acquisition, according to partner Bryan Roberts. The transaction underscores continued strong M&A activity in biotech and is a favorable outcome for venture investors.